Patent Application Titled "Bcma-Targeted Car-T Cell Therapy For Multiple Myeloma" Published Online (USPTO 20240358754).

A patent application titled "Bcma-Targeted Car-T Cell Therapy For Multiple Myeloma" was published online by Legend Biotech USA Inc. The therapy aims to treat multiple myeloma, a neoplasm of plasma cells, by administering T cells with a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA). The method is designed for subjects who have received one to three prior lines of therapies, including immunomodulatory drugs (IMiD), and are refractory to IMiD, with a focus on high-risk features such as cytogenetic abnormalities or International Staging System (ISS) stage III. The therapy shows promise in achieving an overall response rate of 70% to 100%, with stringent complete responses and minimal residual disease negativity. [Extracted from the article]